Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Degarelix Acetate

FDA-approved product (powder, subcutaneous), marketed as Firmagon.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Degarelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Degarelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Degarelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

    NCT04585932 · start 2020-11-24

    Registered record
    Registry ID
    NCT04585932
    Conditions
    Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Degarelix; Leuprolide Acetate; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-11-24
    Completion
    2021-01-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8 +2 more
    InterventionApalutamide; Degarelix; Leuprolide Acetate; Quality-of-Life Assessment +2 more
    PhasePhase 2
    Registry statusWithdrawn

  • Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    NCT04423211 · start 2020-10-08

    Registered record
    Registry ID
    NCT04423211
    Conditions
    Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    3-Dimensional Conformal Radiation Therapy; Apalutamide; Computed Tomography; Degarelix; External Beam Radiation Therapy; Fluciclovine F18; Goserelin Acetate; Intensity-Modulated Proton Therapy; Intensity-Modulated Radiation Therapy; Leuprolide Acetate; Magnetic Resonance Imaging; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Volume Modulated Arc Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2020-10-08
    Completion
    2032-12-31
    Enrolment
    804

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Intervention3-Dimensional Conformal Radiation Therapy; Apalutamide; Computed Tomography; Degarelix +14 more
    PhasePhase 3
    Registry statusRecruiting

  • Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

    NCT04126070 · start 2020-05-11

    Registered record
    Registry ID
    NCT04126070
    Conditions
    Hormone Sensitive Prostate Cancer; Prostate Adenocarcinoma; Metastasis Prostate Adenocarcinoma
    Interventions
    Androgen Deprivation Therapy; Nivolumab; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-05-11
    Completion
    2026-10-30
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Sensitive Prostate Cancer; Prostate Adenocarcinoma; Metastasis Prostate Adenocarcinoma
    InterventionAndrogen Deprivation Therapy; Nivolumab; Docetaxel
    PhasePhase 2
    Registry statusActive not recruiting

  • Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

    NCT04301414 · start 2020-02-25

    Registered record
    Registry ID
    NCT04301414
    Conditions
    Prostate Cancer
    Interventions
    BMS-986218 and Degarelix; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2020-02-25
    Completion
    2025-03-13
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBMS-986218 and Degarelix; Degarelix
    PhaseEarly phase 1
    Registry statusCompleted

  • Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

    NCT04248621 · start 2020-01-23

    Registered record
    Registry ID
    NCT04248621
    Conditions
    Prostatic Neoplasms
    Interventions
    Leuprorelin; Goserelin; Triptorelin; Degarelix; Bicalutamide; Flutamide; Maximum androgen blockade
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-01-23
    Completion
    2022-12-31
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionLeuprorelin; Goserelin; Triptorelin; Degarelix +3 more
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer

    NCT03947151 · start 2019-11-28

    Registered record
    Registry ID
    NCT03947151
    Conditions
    Invasive Ductal Breast Carcinoma
    Interventions
    Degarelix injection(s)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-11-28
    Completion
    2022-08-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Ductal Breast Carcinoma
    InterventionDegarelix injection(s)
    PhasePhase 2
    Registry statusCompleted

  • Bioenergetic Effects of Aging and Menopause (BEAM)

    NCT04043520 · start 2019-09-24

    Registered record
    Registry ID
    NCT04043520
    Conditions
    Menopause; Obesity, Abdominal; Aging; Weight Gain
    Interventions
    GnRH antagonist; Estrogen Product; Placebo estradiol; Placebo GnRH antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2019-09-24
    Completion
    2024-08-31
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Obesity, Abdominal; Aging; Weight Gain
    InterventionGnRH antagonist; Estrogen Product; Placebo estradiol; Placebo GnRH antagonist
    PhasePhase 4
    Registry statusRecruiting

  • FIRMAGON® Intensive Drug Monitoring

    NCT05181800 · start 2019-08-20

    Registered record
    Registry ID
    NCT05181800
    Conditions
    Prostate Cancer
    Interventions
    Degarelix Cohort
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-08-20
    Completion
    2022-12-31
    Enrolment
    1,454

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix Cohort
    PhaseNot recorded
    Registry statusCompleted

  • REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

    NCT03951831 · start 2019-05-16

    Registered record
    Registry ID
    NCT03951831
    Conditions
    Prostate Cancer Metastatic
    Interventions
    REGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-05-16
    Completion
    2028-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionREGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    PhasePhase 2
    Registry statusActive not recruiting

  • Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

    NCT03899077 · start 2019-04-05

    Registered record
    Registry ID
    NCT03899077
    Conditions
    Cancer of Prostate
    Interventions
    Apalutamide; Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial; Goserelin Acetate 10.8 MG Subcutaneous Implant; Triptorelin Pamoate; Degarelix acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-04-05
    Completion
    2025-12
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Prostate
    InterventionApalutamide; Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial; Goserelin Acetate 10.8 MG Subcutaneous Implant; Triptorelin Pamoate +1 more
    PhasePhase 2
    Registry statusUnknown

  • Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    NCT03678025 · start 2018-09-24

    Registered record
    Registry ID
    NCT03678025
    Conditions
    Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone; Bicalutamide; Degarelix; Docetaxel; Flutamide; Goserelin Acetate; Histrelin Acetate; Leuprolide Acetate; Nilutamide; Orchiectomy; Prednisone; Quality-of-Life Assessment; Radiation Therapy; Radical Prostatectomy; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-09-24
    Completion
    2031-10-01
    Enrolment
    1,273

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 more
    InterventionAbiraterone; Bicalutamide; Degarelix; Docetaxel +11 more
    PhasePhase 3
    Registry statusRecruiting

  • Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

    NCT03361735 · start 2018-08-29

    Registered record
    Registry ID
    NCT03361735
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Leuprolide Acetate; Goserelin Acetate; Stereotactic Body Radiation Therapy; Radium Ra 223 Dichloride; Laboratory Biomarker Analysis; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-08-29
    Completion
    2027-01-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionLeuprolide Acetate; Goserelin Acetate; Stereotactic Body Radiation Therapy; Radium Ra 223 Dichloride +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

    NCT03311555 · start 2018-03-28

    Registered record
    Registry ID
    NCT03311555
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-28
    Completion
    2022-12-22
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    PhasePhase 2
    Registry statusCompleted

  • Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

    NCT03112226 · start 2018-02-07

    Registered record
    Registry ID
    NCT03112226
    Conditions
    Cognitive Impairment; Estrogen Deficiency; Menopause; Endothelial Dysfunction; Vascular Stiffness
    Interventions
    GnRHant + E2; GnRHant + Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-02-07
    Completion
    2020-06-21
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognitive Impairment; Estrogen Deficiency; Menopause; Endothelial Dysfunction +1 more
    InterventionGnRHant + E2; GnRHant + Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

    NCT03358563 · start 2018-01-17

    Registered record
    Registry ID
    NCT03358563
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Degarelix; Bicalutamide; Ferumoxytol-enhanced MRI imaging
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-01-17
    Completion
    2022-09-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Degarelix; Bicalutamide; Ferumoxytol-enhanced MRI imaging
    PhaseEarly phase 1
    Registry statusCompleted